fundvisualizer.com

Fidelity® Select Pharmaceuticals PortFPHAX

Performance (before sales charge)

As of 08/31/2023

All information is historical and not indicative of future results. Current performance may be lower or higher than the quoted past performance, which cannot guarantee results. Share price, principal value, and return will vary, and you may have a gain or a loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. After-sales-charge returns reflect the maximum sales charge applicable to the fund. Performance may not reflect any expense limitation or subsidies currently in effect. Short-term trading fees may apply. To obtain the most recent month-end performance, visit Morningstar.com.

Asset allocation

As of 07/31/2023
Stock
55.76%
Non-U.S. Stock
42.75%
Bond
0.00%
Non-U.S. Bond
0.00%
Preferred
0.00%
Convertible
0.00%
Cash
1.03%
Other
0.45%

Due to rounding, percentages may not equal 100%.

Sectors

As of 07/31/2023

Basic materials

0.00%

Consumer cyclical

0.00%

Financial services

0.00%

Real estate

0.00%

Consumer defensive

0.00%

Health care

98.47%

Utilities

0.00%

Communication services

0.00%

Energy

0.00%

Industrials

0.00%

Technology

0.00%

Top 10 holdings

As of 07/31/2023

Eli Lilly and Co
18.09%
AstraZeneca PLC ADR
10.32%
Merck & Co Inc
9.22%
Sanofi SA ADR
7.26%
Novo Nordisk A/S ADR
6.75%
GSK PLC ADR
3.61%
Royalty Pharma PLC Class A
3.43%
UCB SA
3.28%
Gilead Sciences Inc
3.23%
Roche Holding AG
2.97%
Fund assets

$856.87 Million

Share class

No Load

Morningstar category

Health

Expense ratio

0.76%

Investment objective

Specialty - Health

Documents